Tolerance and antiviral effects of high-dose interferon-alpha B/D in patients with chronic hepatitis B.
|
| Abstract |
A novel recombinant interferon-alpha B/D hybrid was applied to assess tolerability, antiviral effect, and biological activity in chronic hepatitis B. The study was designed as an open nonrandomized trial. Treatment comprised a two-week run-in phase with 16 MU three times a week followed by 14 weeks with 64 MU three times a week (or 48 MU if toxicity occurred with 64 MU). Total follow-up was 36 weeks. Nineteen patients were included; three discontinued treatment during the run-in with 16 MU. Fourteen of 16 patients had 14 weeks of treatment with > or = 32 MU three times a week. Fourteen dose reductions were necessary in nine patients. The adverse experience profile was similar to other interferon-alphas. HBV-DNA decreased using all doses studied. HBV-DNA became undetectable in five patients, two of whom had HBeAg seroconversion. No HBsAg seroconversion was observed. It is concluded that interferon-alpha B/D is well tolerated in high doses. The anti-viral effect starts at at least 16 MU three times a week.
|
|---|---|
| Authors | M C Rasch, H Schellekens, C M van Dijck, E B Haagsma, P P Michielsen, A H van Buuren, H Stötter, J van Hattum |
| Journal | Digestive diseases and sciences (Dig Dis Sci) Vol. 43 Issue 8 Pg. 1719-24 (Aug 1998) ISSN: 0163-2116 [Print] United States |
| PMID | 9724159 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!